Aperion Biologics Appoints France Helfer, Mike Ward to Board of Directors

Aperion Biologics announced the appointment of France Dixon Helfer and Mike Ward to its board of directors.

Advertisement

Ms. Helfer currently serves as president and CEO of Halo Healthcare, a medical device and diagnostics company that develops technologies for early risk detection of breast cancer.

 

Mr. Ward has more than 20 years of life sciences-dedicated investment banking, venture capital and private equity experience. He was previously a director at Lurie Investments, where he was responsible for managing investment activities.

 

Aperion Biologics is a privately owned, clinical-stage medical device company.

More Articles on Devices:

5 Key Results: LDR’s Mobi-C Artificial Disc Replacement vs. ACDF
FDA Clears AccelSPINE’s Next Generation Minimally Invasive Spine System
Global Medical Device Market to Grow at 6.2% Annually Until 2018

 

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.